-
1Academic Journal
Source: Клиническая онкогематология, Vol 18, Iss 1 (2025)
-
2Academic Journal
Source: Клиническая онкогематология, Vol 17, Iss 2 (2024)
-
3Academic Journal
Authors: A. V. Smirnov, B. V. Afanasyev, I. V. Poddubnaya, V. A. Dobronravov, M. S. Khrabrova, E. V. Zakharova, E. A. Nikitin, L. V. Kozlovskaya, I. N. Bobkova, V. V. Rameev, M. M. Batyushin, Шю S. Moiseev, E. I. Darskaya, O. V. Pirogova, L. P. Mendeleeva, L. S. Biryukova, А. В. Смирнов, Б. В. Афанасьев, И. В. Поддубная, В. А. Добронравов, М. С. Храброва, Е. В. Захарова, Е. А. Никитин, Л. В. Козловская, И. Н. Бобкова, В. В. Рамеев, М. М. Батюшин, И. С. Моисеев, Е. И. Дарская, О. В. Пирогова, Л. П. Менделеева, Л. С. Бирюкова
Source: The Russian Archives of Internal Medicine; Том 10, № 2 (2020); 102-118 ; Архивъ внутренней медицины; Том 10, № 2 (2020); 102-118 ; 2411-6564 ; 2226-6704 ; 10.20514/2226-6704-2020-0-2
Subject Terms: легкие цепи, monoclonal gammopathy of undetermined significance, onconephrology, kidney injury, clone specific treatment, paraprotein, kidney biopsy, plasma cell dyscrasias, light chains, моноклональная гаммапатия неопределенного значения, онконефрология, поражение почек, клон-ориентированное лечение, парапротеин, нефробиопсия, плазмоклеточные дискразии
File Description: application/pdf
Relation: https://www.medarhive.ru/jour/article/view/1022/890; https://www.medarhive.ru/jour/article/view/1022/899; Leung N, Bridoux F, Hutchison CA et al. Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood 2012;120(22):4292–4295. doi:10.1182/blood-2012-07-445304; Leung N, Bridoux F, Batuman V et al. The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. Nat Rev Nephrol 2019;15(1):45–59. doi:10.1038/s41581-018-0077-4; Козловская ЛВ, Рамеев ВВ, Когарко ИН и др. Поражения почек, ассоциированные с моноклональной гаммапатией неопределенного значения: клинические формы, механизмы развития, подходы к лечению. Клин мед 2016; 94(12):892–901. doi:10.18821/0023-2149-2016-94-12-892-901; Храброва МС, Добронравов ВА, Смирнов АВ. Поражения почек, ассоциированные с моноклональными гаммапатиями: одноцентровое исследование. Нефрология 2018;22(6):38–46. doi:10.24884/1561-6274-2018-22-6-38-46; Захарова ЕВ, Столяревич ЕС. Особенности нефропатий при лимфопролиферативных и плазмоклеточных заболеваниях (опыт одного центра). Альманах клинической медицины 2014;(30):3–11. doi:10.18786/2072-0505-2014-30-3-11; Zakharova EV, Stolyarevich ES. Renal consequences of Lymphoproliferative Disorders and Monoclonal Gammopathy. Urol Nephrol Open Access 2015;2(4):47–55. doi:10.15406/unoaj.2015.02.00047; Zand L, Nasr SH, Gertz MA et al. Clinical and prognostic differences among patients with light chain deposition disease, myeloma cast nephropathy and both. Leuk Lymphoma 2015;56(12):3357–3364. doi:10.3109/10428194.2015; Lin J, Markowitz GS, Valeri AM et al. Renal monoclonal immunoglobulin deposition disease: the disease spectrum. J Am Soc Nephrol 2001;12(7):1482–1492; Nasr SH, Valeri AM, Cornell LD et al. Renal monoclonal immunoglobulin deposition disease: A report of 64 patients from a single institution. Clin J Am Soc Nephrol 2012;7:231–239; Nasr SH, Valeri AM, Cornell LD et al. Fibrillary glomerulonephritis: A report of 66 cases from a single institution. Clin J Am Soc Nephrol 2011;6:775–784; Steiner N, Gobel G, Suchecki P et al. Monoclonal gammopathy of renal significance (MGRS) increases the risk for progression to multiple myeloma: an observational study of 2935 MGUS patients. Oncotarget 2017;9(2):2344–2356. doi:10.18632/oncotarget.23412; Kourelis TV, Nasr SH, Dispenzieri A et al. Outcomes of patients with renal monoclonal immunoglobulin deposition disease. Am J Hematol 2016;91(11):1123–1128. doi:10.1002/ajh.24528; Cohen C, Royer B, Javaugue V et al. Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease. Kidney Int 2015;88:1135–1143; Ziogas DC, Kastritis E, Terpos E, Roussou M et al. Hematologic and renal improvement of monoclonal immunoglobulin deposition disease after treatment with bortezomib-based regimens. Leuk Lymphoma 2017;58(8):1832–1839. doi:10.1080/10428194.2016.1267349; Gumber R, Cohen JB, Palmer MB et al. A clone-directed approach may improve diagnosis and treatment of proliferativeglomerulonephritis with monoclonal immunoglobulin deposits. Kidney Int 2018;94(1):199–205. doi:10.1016/j.kint.2018.02.020; Менделеева ЛП, Вотякова ОМ, Покровская ОС и др. Национальные клинические рекомендации по диагностике и лечению множественной миеломы. Гематология и трансфузиология 2016;61(1, Прил.2):1–24. doi:10.18821/0234-5730-2016-61-1; Российские клинические рекомендации по диагностике и лечению лимфопролиферативных заболеваний под руководством проф. И.В. Поддубной, проф. В.Г. Савченко. 2016 г. Режим доступа: http://www.hematology.ru/oncohematology/standarts/clinical_guidelines-draft.pdf; Dimopoulos MA, Sonneveld P, Leung N et al. International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. J Clin Oncol 2016;34(13):1544–1557. doi:10.1200/JCO.2015.65.0044; Клинические рекомендации по обследованию и лечению больных хроническим лифолейкозом (2014). Коллектив авторов под руководством акад. В.Г. Савченко, проф. И.В. Поддубной. Режим доступа: https://blood.ru/documents/clinical%20guidelines/26.%20klinicheskie-rekomendacii-2014-xll.pdf; Swerdlow SH, Campo E, Pileri SA et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016;127(20):2375–2390. doi:10.1182/blood-2016-01-643569; Kyle RA. Monoclonal gammopathy of undetermined significance. Natural history in 241 cases. Am J Med 1978;64(5):814–826; Vardi A, Dagklis A, Scarfo L et al. Immunogenetics shows that not all MBL are equal: the larger the clone, the more similar to CLL. Blood 2013;121(22):4521–4528. doi:10.1182/blood-2012-12-471698; Kyle RA, Benson J, Larson D et al. IgM monoclonal gammopathy of undetermined significance and smoldering Waldenstrom’s macroglobulinemia. Clin Lymphoma Myeloma 2009;9(1):17–18. doi:10.3816/CLM.2009.n.002; Rajkumar SV, Kyle RA, Buadi FK. Advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undetermined significance: implications for recategorizing disease entities in the presence of evolving scientific evidence. Mayo Clin Proc 2010;85(10):945–948. doi:10.4065/mcp.2010.0520; Merlini G, Stone MJ. Dangerous small B-cell clones. Blood 2006;108 (8):2520–2530. doi:10.1182/blood-2006-03-001164; Fermand JP, Bridoux F, Dispenzieri A et al. Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications. Blood 2018;132(14):1478–1485. doi:10.1182/blood-2018-04-839480; Gertz MA. Waldenstrom macroglobulinemia: 2018 update on diagnosis, risk stratification, and management. Am J Hematol 2018;1–11. doi:10.1002/ajh.25292; Fish R, Pinney J, Jain P et al. The Incidence of major hemorrhagic complications after renal biopsies in patients with monoclonal gammopathies. Clin J Am Soc Nephrol 2010;5(11):1977–1980. doi:10.2215/CJN.00650110; Matsushita K, van der Velde M, Astor BC et al. Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with allcause and cardiovascular mortality in general population cohorts: a collaborative metaanalysis. Lancet 2010;375(9731):2073–2081; Смирнов АВ, Добронравов ВА, Каюков ИГ. Кардио-ренальный континуум: патогенетические основы превентивной нефрологии. Нефрология 2005;9(3):7–15. doi:10.24884/1561-6274-20059-3-7-15; Thomas B, Matsushita K, Abate KH et al. Global Cardiovascular and Renal Outcomes of Reduced GFR. J Am Soc Nephrol 2017;28(7):2167– 2179. doi:10.1681/ASN.2016050562; van der Velde M, Matsushita K, Coresh J et al. Chronic Kidney Disease Prognosis Consortium: Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int 2011;79:1341–1352; Hui X, Matsushita K, Sang Y et al. CKD and cardiovascular disease in the Atherosclerosis Risk in Communities (ARIC) study: Interactions with age, sex, and race. Am J Kidney Dis 2013; 62: 691–702; Kyle RA, San-Miguel JF, Mateos MV, Rajkumar SV. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Hematol Oncol Clin North Am 2014;28(5):775–790. doi:10.1016/j.hoc.2014.06.005; Buxbaum JN, Hurley ME, Chuba J, Spiro T. Amyloidosis of the AL type. Clinical, morphologic and biochemical aspects of the response to therapy with alkylating agents and prednisone. Am J Med 1979;67(5):867–878; Benson MD. Treatment of AL amyloidosis with melphalan, prednisone, and colchicine. Arthritis Rheum 1986;29(5):683–687; Vaxman I, Gertz M. Recent Advances in the Diagnosis, Risk Stratification, and Management of Systemic Light-ChainAmyloidosis. Acta Haematol 2019;141(2):93–106; Zakharova EV, Stolyarevich ES. Chemotherapy for renal AL amyloidosis: treatment results and outcomes in 49 patients from a single center. Clinical Practice 2016;13(1):11–18; Fermand JP, Bridoux F, Kyle RA et al. How I treat monoclonal gammopathy of renal significance (MGRS). Blood 2013;122(22):3583– 3590. doi:10.1182/blood-2013-05-495929; Heilman RL, Velosa JA, Holley KE et al. Long-term follow-up and response to chemotherapy in patients with light-chain depositiondisease. Am J Kidney Dis 1992;20(1):34–41; Cohen C, Royer B, Javaugue V et al. Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease. Kidney Int 2015; 88: 1135–1143; Gavriatopoulou M, Musto P, Caers J et al. European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. Leukemia 2018; 32(9):1883–1898. doi:10.1038/s41375-018-0209-7; Ziogas DC, Kastritis E, Terpos E et al. Hematologic and renal improvement of monoclonal immunoglobulin deposition disease after treatment with bortezomib-based regimens. Leuk Lymphoma 2017;58(8):1832–1839. doi:10.1080/10428194.2016.1267349; Nasr SH, Markowitz GS, Stokes MB et al. Proliferative glomerulonephritis with monoclonal IgG deposits: a distinct entity mimicking immune-complex glomerulonephritis. Kidney Int 2004; 65(1):85–96; Nasr SH, Snyder RW, Bhagat G, Markowitz GS. Chronic lymphocytic leukemia and cryoglobulinemic glomerulonephritis. Kidney Int 2007;71(2):93; Herrera GA, Joseph L, Gu X et al. Renal pathologic spectrum in an autopsy series of patients with plasma cell dyscrasia. Arch Pathol Lab Med 2004;128(8):875–879; Ciocchini M, Arbelbide J, Musso CG. Monoclonal gammopathy of renal significance (MGRS): the characteristics and significance of a new meta-entity. Int Urol Nephrol 2017;49(12):2171–2175. doi:10.1007/s11255-017-1594-y; Kanzaki G, Okabayashi Y, Nagahama K et al. Monoclonal Immunoglobulin Deposition Disease and Related Diseases. J Nippon Med Sch 2019;86(1):2–9. doi:10.1272/jnms.JNMS.2019_86-1; Caravaca-Fontan F, Gutierrez E, Delgado Lillo R, Praga M. Monoclonal gammopathies of renal significance. Nefrologia 2017;37(5):465–477. doi:10.1016/j.nefro.2017.03.012; Mehtat Unlu Ş, Ozsan H, Sarıoğlu S et al. The Scope of Kidney Affection in Monoclonal Gammopathies at All Levels of Clinical Significance. Turk J Haematol 2017;34(4):282–288. doi:10.4274/tjh.2017.0197; Sethi S, Rajkumar SV. Monoclonal gammopathy-associated proliferative glomerulonephritis. Mayo Clin Proc 2013; 88(11):1284– 1293. doi:10.1016/j.mayocp.2013.08.002; Bridoux F, Leung N, Hutchison CA et al. Diagnosis of monoclonal gammopathy of renal significance. Kidney Int 2015; 87(4):698–711. doi:10.1038/ki.2014.408; Режим доступа: https://icd.who.int/browse11/l-m/en#/http%3a%2f%2fid.who.int%2ficd%2fentity%2f1815409370; Sethi S, Rajkumar SV, D’Agati VD. The Complexity and Heterogeneity of Monoclonal Immunoglobulin-Associated Renal Diseases. J Am Soc Nephrol 2018;29(7):1810–1823. doi:10.1681/ASN.2017121319; Larsen CP, Messias NC, Walker PD et al. Membranoproliferative glomerulonephritis with masked monotypic immunoglobulin deposits. Kidney Int 2015;88(4):867–873. doi:10.1038/ki.2015.195; Nasr SH, Fidler ME, Said SM. Paraffin Immunofluorescence: A Valuable Ancillary Technique in Renal Pathology. Kidney Int Rep 2018;3(6):1260–1266. doi:10.1016/j.ekir.2018.07.008; Messias NC, Walker PD, Larsen CP et al. Paraffin immunofluorescence in the renal pathology laboratory: more than a salvage technique. Mod Pathol 2015;28(6):854–860. doi:10.1038/modpathol.2015.1; Alexander MP, Dasari S, Vrana JA et al. Congophilic Fibrillary Glomerulonephritis: A Case Series. Am J Kidney Dis 2018; 72(3):325–336. doi:10.1053/j.ajkd.2018.03.017; Nasr SH, Vrana JA, Dasari S et al. DNAJB9 Is a Specific Immunohistochemical Marker for Fibrillary Glomerulonephritis. Kidney Int Rep 2017;3(1):56–64. doi:10.1016/j.ekir.2017.07.017; Herrera GA, Sanders PW, Reddy BV. Ultrastructural immunolabeling: a unique diagnostic tool in monoclonal light chain–related renal diseases. Ultrastruct Pathol 1994;18:401–416; Gu X, Herrera GA. Light-chain-mediated acute tubular interstitial nephritis: a poorly recognized pattern of renaldisease in patients with plasma cell dyscrasia. Arch Pathol Lab Med 2006; 130(2):165–169; Royal V, Quint P, Leblanc M et al. IgD heavy-chain deposition disease: detection by laser microdissection and mass spectrometry. J Am Soc Nephrol 2015;26(4):784–790. doi:10.1681/ASN.2014050481; Leung N, Barnidge DR, Hutchison CA et al. Laboratory testing in monoclonal gammopathy of renal significance (MGRS). Clin Chem Lab Med 2016;54(6):929–937. doi:10.1515/cclm-2015-0994; Rosner MH, Edeani A, Yanagita M et al. Paraprotein–related kidney disease: diagnosing and treating monoclonal gammopathy of renal significance. Clin J Am Soc Nephrol 2016;11(12): 2280–2287. doi:10.2215/CJN.02920316; Gertz MA. Immunoglobulin light chain amyloidosis: 2016 update on diagnosis, prognosis, and treatment. Am J Hematol 2016;91(9):947– 956. doi:10.1002/ajh.24433; Pasquali S, Iannuzzella F, Corrandini M et al. A novel option for reducing free light chains in myeloma kidney: Supra-hemodiafiltration with endogenous reinfusion (HFR). J Nephrol 2015;28(2):251–254; Pendon-Ruiz de Mier MV, Alvarez-Lara MA et al. Effectiveness of haemodiafiltration with ultrafiltrate regeneration in the reduction of light chains in multiple myeloma with renal failure. Nefrologia 2013;33(6):788–796; Mene P, Giammarioli E, Fofi C et al. Serum free light chains removal by HFR hemodiafiltration in patients with multiple myeloma and acute kidney injury: a case series. Kidney Blood Press Res 2018;43(4):1263– 1272; Sayed RH, Wechalekar AD, Gilbertson JA et al. Natural history and outcome of light chain deposition disease. Blood 2015;126(26):2805– 2810. doi:10.1182/blood-2015-07-658872; Decourt A, Gondouin B, Delaroziere JC et al. Trends in survival and renal recovery in patients with multiple myeloma or light-chain amyloidosis on chronic dialysis. Clin J Am Soc Nephrol 2016; 11(3):431–441. doi:10.2215/CJN.06290615; Abudayyeh AA, Lahoti A, Salahudeen AK et al. Onconephrology: the need and the emergence of a subspecialty in nephrology. Kidney Int 2014;85(5):1002–1004. doi:10.1038/ki.2014.29; Cohen EP, Krzesinski JM, Launay-Vacher V, Sprangers B. Onconephrology: Core Curriculum 2015. Am J Kidney Dis 2015;66(5):869– 883. doi:10.1053/j.ajkd.2015.04.042; Cosmai L, Porta C, Perazella MA et al. Opening an onconephrology clinic: recommendations and basic requirements. Nephrol Dial Transplant 2018;33(9):1503–1510. doi:10.1093/ndt/gfy188; Capasso A, Benigni A, Capitanio U et al. Summary of the International Conference on Onco-Nephrology: an emerging field in medicine. Kidney Int 2019; article in press. doi:10.1016/j.kint.2019.04.043; https://www.medarhive.ru/jour/article/view/1022